BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, December 6, 2025
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 24, 2003
View Archived Issues
Spotlight on new drugs to treat female sexual dysfunction
Read More
Spotlight on "diabesity"
Read More
NIAID grant for inhaled biodefense drug development at Coley
Read More
TaiGen and TTY Biopharm sign joint development, marketing agreement for DB-67
Read More
New inhibitors of FAK and other kinases developed at Aventis Pharma
Read More
Aventis claims new protein kinase inhibitors for use in neurological disorders
Read More
AstraZeneca describes a novel series of dual CCR3 modulators/H1 antagonists
Read More
Schering-Plough claims new NK1 antagonists for emesis, anxiety, depression, etc.
Read More
New muscarinic M3 antagonists covered by Boehringer Ingelheim patent
Read More
Japanese researchers identify c-fos expression modulators for cancer therapy
Read More
GSK scientists present novel antibacterial PDF inhibitors
Read More
Long-term evaluation of anastrozole and tamoxifen in postmenopausal women with breast cancer
Read More
A novel pneumococcal vaccine reported effective in children with or without HIV
Read More
NO-releasing aspirin protects against gastrointestinal damage caused by low-dose aspirin
Read More
Eberconazole as an alternative to miconazole in dermatophytosis
Read More
Aspreva to develop CellCept for autoimmune diseases
Read More
AVP-13358 well tolerated in phase I trial
Read More
Baxter completes acquisition of Aralast
Read More
Shionogi obtains Japanese distribution rights to moxifloxacin
Read More
Rolling NDA submission for clofarabine begins
Read More
DOV to purchase Elan's stake in joint venture
Read More
Forest proceeds with expanded program of memantine for neuropathic pain
Read More
Phase II trial evaluates pixantrone as part of BSHAP regimen for NHL
Read More
Approvable letter issued for Foradil Certihaler
Read More
Fast track status for T-67 in hepatocellular carcinoma
Read More
Potent JAK3 inhibitor shows efficacy in ear edema model
Read More
Specific bradycardic agent with oral activity designed by Japanese researchers
Read More